title: ASPREE-D: Aspirin for the prevention of depression in the elderly.
abstract: Not only is depression associated with increased inflammation but inflammation is a risk factor for the genesis of depression. Many of the environmental risk factors for depression are transduced through inflammatory signaling. Anti-inflammatory agents show promise for the management of depression in preclinical, epidemiological, and early clinical studies. This opens the door to the potential for anti-inflammatory agents to treat and prevent depression. There are no evidence-based pharmacotherapies for depression prevention.
  
  
  
  ASPREE-D, aspirin in the prevention of depression in the elderly, is a sub study of ASPREE, which explores the potential of aspirin to prevent a range of inflammation related disorders in the elderly. With a sample size of 19,114, and a duration of 5 years, this placebo controlled study will be one of the largest randomized controlled trials in psychiatry and will provide definitive evidence on the ability of aspirin to prevent depression.
  
  
  
  This paper presents the rationale for the study and presents a summary of the study design.
  
  
  
  ASPREE-D may not only define novel therapy but will provide mechanistic proof of concept of the role of inflammation in depression.
authors: Deakin University,School of Medicine,IMPACT Strategic Research Centre,Barwon Health,Geelong,Victoria,Australia.
authors: Michael
authors: M
authors: Berk
authors: School of Public Health and Preventive Medicine,Monash University,Melbourne,Victoria,Australia.
authors: R L
authors: RL
authors: Woods
authors: Menzies Institute for Medical Research,University of Tasmania,Tasmania,Australia.
authors: M R
authors: MR
authors: Nelson
authors: Department of Family Medicine and the Rush Alzheimer's Disease Center,Rush University Medical Center,Chicago,Illinois,USA.
authors: R C
authors: RC
authors: Shah
authors: School of Public Health and Preventive Medicine,Monash University,Melbourne,Victoria,Australia.
authors: C M
authors: CM
authors: Reid
authors: Central Clinical School,Monash University,Victoria,Australia.
authors: E
authors: E
authors: Storey
authors: School of Public Health and Preventive Medicine,Monash University,Melbourne,Victoria,Australia.
authors: S M
authors: SM
authors: Fitzgerald
authors: School of Public Health and Preventive Medicine,Monash University,Melbourne,Victoria,Australia.
authors: J E
authors: JE
authors: Lockery
authors: School of Public Health and Preventive Medicine,Monash University,Melbourne,Victoria,Australia.
authors: R
authors: R
authors: Wolfe
authors: Deakin University,School of Medicine,IMPACT Strategic Research Centre,Barwon Health,Geelong,Victoria,Australia.
authors: M
authors: M
authors: Mohebbi
authors: Berman Center for Outcomes & Clinical Research,Hennepin County Medical Center,Minneapolis,Minnesota,USA.
authors: A M
authors: AM
authors: Murray
authors: Berman Center for Outcomes & Clinical Research,Hennepin County Medical Center,Minneapolis,Minnesota,USA.
authors: B
authors: B
authors: Kirpach
authors: Berman Center for Outcomes & Clinical Research,Hennepin County Medical Center,Minneapolis,Minnesota,USA.
authors: R
authors: R
authors: Grimm
authors: School of Public Health and Preventive Medicine,Monash University,Melbourne,Victoria,Australia.
authors: J J
authors: JJ
authors: McNeil
mesh_terms: D000368:Aged; D000893:Anti-Inflammatory Agents / Q000008:administration & dosage; D001241:Aspirin / Q000008:administration & dosage*; D003863:Depression / Q000503:physiopathology / Q000517:prevention & control; D004311:Double-Blind Method; D005260:Female; D006801:Humans; D007249:Inflammation / Q000188:drug therapy / Q000523:psychology; D008297:Male; D012107:Research Design
chemical_list: D000893:Anti-Inflammatory Agents; D001241:Aspirin
keywords: antidepressants; aspirin; biomarkers; depression; immunology; inflammation; prevention; risk